Block Test Page
This page is used to verify the rendering of custom Ardena Gutenberg blocks. Each section below tests one block in isolation.
1. Section Header block
From Complexity to Clarity
Ardena is your scientific partner from preclinical through clinical phase, delivering integrated CMC solutions for small molecules and biologics.
We accelerate your drug development
A centered alignment variant of the section header block, with the badge and heading aligned to the middle of the container.
2. Icon block
Six icon variations (rounded square + circle, in brand colors).
3. Colored Card block
Three cards in a 3-column layout, each with a different brand color, icon, and content. The third has an optional link.
Drug Substance
From discovery to commercial supply, our scientists develop and manufacture API for early phase through late phase.
Drug Product
Formulation, analytical and manufacturing services for solid and injectable drug products at any clinical stage.
A second row with the remaining brand colors:
Solid State Research
Polymorph screening, salt selection, co-crystals and amorphous dispersions to optimize drug performance.
Bioanalysis
Method development, validation and sample analysis for small molecules, biologics and biomarkers.
4. Accordion block
Burgundy accent. Click each row to expand.
Solid state research investigates the physicochemical form of an API. We look at polymorphs, salts, co-crystals and amorphous forms to find the most stable and bioavailable solid form for your candidate.
A typical polymorph screen runs 6–10 weeks, depending on solvent space and analytical depth. We can run a short triage screen in 2–3 weeks if speed is critical.
Yes — Ardena holds the licensing and infrastructure to process Schedule I–IV controlled substances and high potency compounds in dedicated suites.
Magenta accent variant:
We provide patent landscape analysis, freedom-to-operate reviews, and prior-art mapping aligned with your filing strategy.
All deliverables are exchanged via an encrypted client portal with role-based access and full audit trails.
5. Timeline block
Alternating left-right cards on desktop, stacked on mobile. Five milestones across the brand color palette.
Foundation
Ardena founded with a vision to integrate CMC services across small and complex molecules.
Solid State Centre of Excellence
Opened our dedicated solid state research facility and expanded crystallization capacity.
Bioanalysis Platform
Launched regulated bioanalysis services covering small molecules, peptides and biologics.
Clinical Supply Network
Connected European packaging hubs to a global investigator-site distribution network.
Integrated CMC Platform
Today Ardena delivers end-to-end CMC programs from milligram to commercial scale.
6. Platform Tabs block
Click each tab to switch the colored content panel.
Small Molecule Development
From discovery support to commercial supply, we cover crystallization, formulation and analytics for small molecule APIs.
Discuss Your ProgramPeptide Therapeutics
Specialized peptide synthesis, purification and stability programs aligned with your clinical milestones.
Talk to a Peptide LeadBiologics Programs
Cell-line, upstream and downstream support for complex biologic candidates entering early-phase clinical work.
Start a Biologics ProjectConjugate Therapeutics
Linker chemistry, payload conjugation and analytical characterization for antibody-drug and X-drug conjugates.
Plan a Conjugate Program7. Resource Carousel — taxonomy filter
Auto-pulls the latest Application Notes from the Resources CPT (filtered by the “Application Note” content type).
Related Application Notes
Selected reading from our solid state and formulation teams.
Resource Carousel — Whitepapers
Same block configured to show only Whitepapers on a burgundy background. Auto-advance off.
Featured Whitepapers
In-depth pieces from our scientific teams.
-
Whitepapers
Advancing Pharmaceutical Production: The Benefits of Flow Manufacturing for Nanomedicines
Read more -
Whitepapers
Evolution of Stability Guidelines: From the ICH Q1A-F Series to the Consolidated ICH Q1 Guideline
Read more -
Whitepapers
Deciphering the Complex Characteristics of Nanomedicine
Read more -
Whitepapers
Late-Stage Development and Manufacturing of Novel Excipients for Precision Nanomedicines and Targeted Therapies
Read more -
Whitepapers
Innovations in API Manufacturing of Small Molecule Drugs
Read more -
Whitepapers
(Cross-)Contamination Control through Effective Equipment Cleaning
Read more -
Whitepapers
Solid State Chemistry and Strategic Outsourcing
Read more -
Whitepapers
Streamlining Early Drug Development: Efficient Synthesis of Highly Potent Compounds
Read more -
Whitepapers
Exploring the Science and Technology Behind Fractionation, Purification, and Downstream Processing: From Discovery to Commercialization
Read more
Leadership Carousel block
Editor-curated. Lets you pick cpt-team members in the sidebar and reorder. Horizontally scrollable cards with snap points and prev/next arrows. Magenta section background with decorative blobs and rings.
Leadership Team
Our leadership team has a deep understanding and exceptional experience in their respective fields of expertise which we leverage to guide our approach and deliver the best possible outcomes for our partners.
Chief Scientific Officer
Since 2019, Ariane has overseen Ardena’s drug product activities, spearheading successful integration and transformation at Ardena Pamplona and expanding the company’s capabilities to include sterile services.
Global Head, CRO
Gunnar Flik joined Ardena in 2024 as Division Head of Bioanalytical Services. With over 20 years of experience in drug discovery within biotech and CRO environments, Gunnar brings a wealth of strategic vision and entrepreneurial expertise to his role. He is dedicated to developing comprehensive short- and long-term strategic plans aimed at optimizing efficiency, fostering growth, and enhancing profitability within Ardena’s Bioanalysis division.
Head of Drug Product Europe
Arnout Everaert is Head of Drug Product Europe at Ardena, where he leads the company’s drug product development and manufacturing strategy across its European operations.
Non-Executive Director
Alan has over 30 years private equity experience, witrh a strong track record of dedicated healthcare investing. Alan is currently a member of the board at Ardena, Sterling, Alcami, RoslinCT, and X-Chem and previously Quotient Sciences until its successful exit. Previously, Alan was a board member at 3i plc, led the build-out of the 3i Europe office network, and founded 3i’s healthcare sector team as Global Head of Healthcare. Subsequently, Alan was founder, CEO and Chairman of the Investment Committee at Hermes GPE, an active co-investor in private equity-backed healthcare.
Non-Executive Director
Sabina is an investment professional with a background in both accounting and corporate finance. Having joined GHO in 2015, Sabina currently works closely with Ardena and DDC, as well as previously with Caprion Biosciences prior to GHO Capital’s successful exit. Prior to GHO, Sabina was with 123Venture in Paris where she was responsible for evaluating and executing mezzanine financing opportunities across Europe.
Facilities Carousel block
Auto-listing. Renders all published cpt-locations posts ordered by menu_order. No editor picker — the list reflects whatever published locations exist. Capability tags come from the location services repeater.
